Ironwood IPO Raises Plenty Of Cash And Plenty Of Questions For Biotech Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
The much-anticipated debut of the constipation-drug developer hits $188 million, but a venture owner had to buy nearly half the issue.
You may also be interested in...
Ironwood Adds A China Wrinkle To Regional Deal Strategy
The December US launch of linaclotide is a transformative event for Ironwood Pharmaceuticals, the GI drug’s discoverer. But the company’s recent deal with AstraZeneca to sell the drug in China represents another kind of feat and highlights the growing importance of regional deals to Western biotechs.
Strong Phase III Data Have Linaclotide On Track For Filing In 2011
Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.
Strong Phase III Data Have Linaclotide On Track For Filing In 2011
Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.